Norling, Lucy

Dr Lucy Norling

Arthritis Research UK Fellow

Lucy Norling graduated in Applied and Human Biology (BSc) from Aston University, Birmingham in 2003, followed by a Masters in Research and PhD at the William Harvey Research Institute, Queen Mary University of London in 2008. Dr. Norling was then awarded 3 year Arthritis Research UK Foundation Fellowship and spent two years training at Harvard Medical School, Boston, with the mentorship of Professor Charles Serhan. In 2012 Dr Norling attained a 5 year Arthritis Research UK Career Development Fellowship to further her studies on the role of resolvins in inflammatory arthritis. 

Summary of Research

Bioactive lipid mediators in resolution of Inflammation

My interests are investigating the bioactions of novel lipid mediators that are derived from omega-3 fatty acids, in particular the DHA-derived Resolvins. These endogenous mediators have anti-inflammatory and pro-resolving properties and may explain the protective effects seen in RA patients taking fish oil supplements. My research focuses on the mechanisms by which Resolvins limit leukocyte recruitment to inflammatory sites, a hallmark of the inflammatory response. With Arthritis Research UK, I spent two years training at Harvard Medical School, Boston, with the mentorship of Professor Charles N. Serhan, who pioneered this field. My future research plans are to investigate whether dysfunctional pathways in the generation of these lipid mediators exist in chronic inflammatory pathologies such as RA.

 

Members of the Group

PhD students: Rachael Wright; Patrícia Souza

Key Publications

For a full list of publist publications click here
 
Norling LV, Dalli J, Flower RJ, Serhan CN, Perretti M. Resolvin D1 limits polymorphonuclear leukocyte recruitment to inflammatory loci: receptor-dependent actions. Arterioscler Thromb Vasc Biol. 2012 Aug;32(8):1970-8. doi:10.1161/ATVBAHA.112.249508. Epub 2012 Apr 12. PubMed PMID: 22499990; PubMed Central PMCID: PMC3401489.
 
Norling LV, Spite M, Yang R, Flower RJ, Perretti M, Serhan CN. Cutting edge: Humanized nano-proresolving medicines mimic inflammation-resolution and enhance wound healing. J Immunol. 2011 May 15;186(10):5543-7. doi:10.4049/jimmunol.1003865. Epub 2011 Apr 1. PubMed PMID: 21460209; PubMed Central PMCID: PMC3145138.
 
Spite M, Norling LV, Summers L, Yang R, Cooper D, Petasis NA, Flower RJ, Perretti M, Serhan CN. Resolvin D2 is a potent regulator of leukocytes and controls microbial sepsis. Nature. 2009 Oct 29;461(7268):1287-91. doi:10.1038/nature08541. PubMed PMID: 19865173; PubMed Central PMCID: PMC2779525.
 
Norling LV, Sampaio AL, Cooper D, Perretti M. Inhibitory control of endothelial galectin-1 on in vitro and in vivo lymphocyte trafficking. FASEB J. 2008 Mar;22(3):682-90. Epub 2007 Oct 26. PubMed PMID: 17965266.
 
Dalli J, Norling LV, Renshaw D, Cooper D, Leung KY, Perretti M. Annexin 1 mediates the rapid anti-inflammatory effects of neutrophil-derived microparticles. Blood. 2008 Sep 15;112(6):2512-9. doi:10.1182/blood-2008-02-140533. Epub 2008 Jul 1. PubMed PMID: 18594025.
 
^ Back to Top